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EMERGING ISSUES IN FDA
REGULATION: WARNING LETTERS,
INTERNET PROMOTION, AND
TOBACCO
JEFFREY M. SENGER*
The mission of the United States Food and Drug Administration (FDA) is to
protect and promote the public health. The agency is charged with assuring the
safety of America's foods; the safety, efficacy, and security of human and
veterinary drugs, biological products, and medical devices; and the safety and
security of cosmetics and products that emit radiation. Americans spend close to
$1.5 trillion a year on these products-about twenty percent of the entire consumer
economy.' The FDA's Office of Chief Counsel (OCC) manages the legal work of
the agency. This Article will discuss the organization of OCC,2 along with several
important issues now facing the agency: warning letters,3 Internet promotion,4 and
tobacco.5
I. ORGANIZATION OF OCC
OCC currently has about ninety lawyers and twenty support staff. The
lawyers serve as both litigators and counselors. The litigators (about one-third of
the office) represent FDA in federal court. OCC participates in both affirmative
civil litigation (where the agency sues parties for violating the law) and defensive
civil litigation (where parties sue FDA when they believe the agency has violated
the law). The litigation team also includes about a dozen lawyers who prosecute
criminal matters.
Copyright © 2010 by Jeffrey M. Senger.
* Deputy Chief Counsel for the United States Food and Drug Administration, Department of Health and
Human Services. A.B., Harvard College; J.D., Harvard Law School. This Article was adapted from the
author's keynote speech for the Emerging Issues in Food and Drug Law: A National Conference for
Lawyers, Policy-Makers, and Corporate Leaders, which was held at the-University of Maryland School
of Law on November 16, 2009.
1. U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., FISCAL YEAR 2010:
JUSTIFICATION OF ESTIMATES FOR APPROPRIATIONS COMMITTEES 2 (2009), http://www.fda.gov/
downloads/AboutFDA/ReportsManualsForms/Reports/BudgetReportsl/UCM 153491 .pdf.
2. See infra Part 1.
3. See infra Part II.
4. See infra Part Ill.
5. See infra Part IV.
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OCC lawyers work with the Justice Department on all federal court litigation.
Justice Department lawyers generally take the lead in making in-court arguments
and serve as "first chair" in trials. OCC lawyers also participate in some arguments
and trials, and they often take the lead on brief-writing, as they may have more
substantive experience with FDA laws and regulations-particularly when working
with an Assistant United States Attorney, as these lawyers must handle a wide
variety of subject matters. A more specialized office within the Justice Department,
the Office of Consumer Litigation, handles certain FDA-related matters. Because of
their greater familiarity with FDA laws, this office often plays a more substantive
role in litigation when it is involved.
OCC's counselors work with each of the FDA's product centers, advising the
agency on legal matters involving drugs, biologic products, devices, foods, animal
products, and now tobacco. They handle most agency issues that do not involve
litigation and also advise litigators on certain litigation matters. They participate in
agency rulemaking, review guidances, advise on legislation, clear press releases,
handle administrative law questions, and provide counsel on legal issues involved
with agency programs.
OCC is officially part of the Office of General Counsel of the Department of
Health and Human Services (HHS). Thus, while OCC advises the FDA on a daily
basis, it is not organizationally a part of the FDA. Instead, the office reports to the
General Counsel of HHS, with a "dotted-line" relationship to the FDA
Commissioner.6 At the same time, the FDA pays the salaries of OCC employees,
and OCC offices are co-located with FDA staff in suburban Maryland, rather than
in downtown Washington, D.C., with most HHS staff.
FDA is itself a component of HHS, and the FDA Commissioner reports to the
Secretary of HHS, who reports to the President.7 Thus, the FDA is not an
independent agency (like the Securities and Exchange Commission or the Federal
Trade Commission), but rather it is a part of the presidential administration. This
affects the agency in a number of ways. All testimony that FDA officials give
before Congress must be reviewed and approved by the White House Office of
Management and Budget, which often sends the testimony to other executive
branch agencies for comment.8 Annual FDA budget requests are made by the
President as part of the administration's formal budget. As mentioned above, all
statements the agency makes in court must be approved by the Justice Department.
6. U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., OFFICE OF THE
COMMISSIONER: ORGANIZATION CHART, http://www.fda.gov/downfoads/AboutFDA/CentersOffices/
OrganizationChartsUCM182115.pdf; U.S. Dep't of Health & Human Servs., Office of the General
Counsel Organization Chart, http://www.hhs.gov/about/orgchart/ogc.html (last visited May 31, 2010).
7. See U.S. Dep't of Health & Human Servs., U.S. Department of Health and Human Services
Organization Chart, http://www.hhs.gov/about/orgchart/ (last visited May 31, 2010).
8. Cf Exec. Order No. 12866, 58 Fed. Reg. 51,735, 51,737 (Oct. 4, 1993) (describing the review
function of the Office of Management and Budget).
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That said, there are a relatively small number of political appointees at FDA.
At noon on January 20, 2009, when President Obama took office, only three
political positions changed hands: the Commissioner, the Chief Counsel, and the
Special Assistant to the Commissioner.9 To be sure, these are top positions in the
agency, and while only three political positions turned over upon inauguration,
some others left before the end of the administration. Nonetheless, the great bulk of
the day-to-day work of the agency is done by its roughly 12,000 career
employees, o
FDA works closely with many other federal agencies to fulfill its mission.
Key partners include the Department of Justice on court litigation; the Federal
Trade Commission on advertising issues; the Department of Agriculture on food
matters; the Environmental Protection Agency on environmental and pesticide
issues; the Federal Bureau of Investigation on criminal matters; the Department of
State on international issues; the Customs Service on imported products; the Postal
Service on mail fraud; the Alcohol and Tobacco Tax and Trade Bureau at the
Treasury Department on alcohol and tobacco issues; the Drug Enforcement
Administration on controlled substances; and more. Careful coordination is vital to
ensure the government takes appropriate positions that meet the needs of all of
these agencies.
OCC is headed by the Chief Counsel, who in recent years, and at various
times in the past, has been appointed by the President." The Chief Counsel is
assisted by the Deputy Chief Counsel, who works on overall management of the
office; the Deputy Chief Counsel for litigation, who supervises court-related
matters; and the Deputy Chief Counsel for Program Review, who leads the
counselors. The management team also includes three Associate Deputy Chief
Counsels, one for litigation and two for counseling, and an Executive Officer.
The Chief Counsel (and, from time to time, the Deputy Chief Counsel)
participates in a number of daily meetings with FDA leadership. Every Tuesday
and Thursday, the Commissioner, Deputy Commissioners, and Chief Counsel meet
at 8:45 a.m. in the Commissioner's office at the White Oak complex in Silver
Spring, Maryland. Participants report on upcoming events of the day, discuss high-
level agency management issues, and strategize about agency priorities. On
9. S. COMM. ON HOMELAND SECURITY & Gov'T AFF., 110TH CONG., UNITED STATES
GOVERNMENT: POLICY AND SUPPORTING POSITIONS 72-74 [hereinafter PLUMBOOK] (Comm. Print
2008), available at http://www.gpoaccess.gov/plumbook/2008/2008_plum-book.pdf.
10. See, e.g., Nomination ofAndrew von Eschenbach and Paul Decamp: Hearing of the Comm. on
Health, Education, Labor, and Pensions, 109th Cong. 11 (2006) (statement of Andrew von Eschenbach,
Nominee to be Commissioner of Food and Drugs, Department of Health and Human Services),
available at http://bulk.resource.org/gpo.gov/hearings/109s/30085.pdf (describing the "over-12,000
incredibly talented and highly trained professionals and staff... [as] epitomiz[ing] the true meaning of
the word 'public servant"').
11. See PLUMBOOK, supra note 9, at 67 (listing the Associate General Counsel, Food and Drug
Division as a noncareer appointment).
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Mondays, Wednesdays, and Fridays, this group is joined by other senior staff
members, including the Associate Commissioner for Regulatory Affairs, the
Assistant Commissioner for Public Affairs, the Assistant Commissioner for
Legislation, and the Directors of each of the Centers (drugs, biologics, devices,
foods, veterinary medicine, and tobacco). Attendees report on activities of their
office, including upcoming events. During crisis situations, such as an emerging
outbreak, additional meetings are added (such as a recent 7:45 a.m. daily food
safety meeting).
Attorneys in OCC also meet often with outside parties. Outside lawyers
request meetings with our litigators to discuss pending or potential lawsuits, and
with counselors to discuss actions they, or the agency, have taken or plan to take.
Many times, OCC lawyers will schedule separate meetings with parties on each
side of a dispute to ensure everyone has an opportunity to be heard. Meetings with
OCC are focused on legal issues. A brief description of all meetings with the Chief
Counsel is posted on the internet (consisting of a listing of all attendees and a
general description of the topic). 12 Sometimes parties attempt to schedule meetings
with OCC on scientific or policy issues, but these are more appropriately referred
to the Centers or the Office of Policy.
I. WARNING LETTER INITIATIVES
A significant recent initiative at FDA involves inspections and warning
letters. Upon completion of an inspection of a regulated facility, an FDA form 483
is given to the facility's management to notify them of apparent violations that
were observed during the inspection.' 3 The form lists observations without
constituting a final agency determination of a violation.14 It requests that the
company make any objections to the findings and provide plans to implement
corrective action. 1
When FDA determines that an establishment is in violation of the law, the
agency may issue a warning letter.' 6 The agency sends a warning letter only for
12. See U.S. Food & Drug Admin., 2010 Public Calendars, http://www.fda.gov/NewsEvents/
MeetingsConferencesWorkshops/PastMeetingsWithFDAOfficials/201 OPublicCalendars/default.htm
(last visited May 31, 2010) (listing "significant meetings held by FDA policy makers with persons
outside the executive branch" for 2010).
13. See U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., INVESTIGATIONS
OPERATIONS MANUAL 225-26 (2010), available at http://www.fda.gov/downloads/lCEClInspections/
IOM1UCM 150576.pdf (instructing that the FDA form 483 is to be used to notify the inspected facility in
writing of its significant violations that were observed during the inspection).
14. Id. at 226.
15. Id.
16. See U.S. FOOD & DRUG ADMIN., U.S. DEP'T OF HEALTH & HUMAN SERVS., REGULATORY
PROCEDURES MANUAL 4-1 (2010), available at http://www.fda.gov/downloadsflCECI/
ComplianceManuals/RegulatoryProceduresManual/UCM074330.pdf ("Warning Letters are issued to
achieve voluntary compliance and to establish prior notice.... The use of Warning Letters and the prior
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significant violations that may lead to enforcement action if the company does not
promptly and adequately correct them. 17 Senior FDA officials conduct a thorough
review of all relevant facts before issuing a warning letter.'8
In the past, some inspected companies submitted multiple responses to the
FDA form 483 inspectional reports, sometimes spanning over many months.
9
Delays sometimes resulted while the agency reviewed these submissions.20 FDA
believes this does not always serve public interest, as prompt issuance of warning
letters can promote compliance with the law.21 Warning letters ensure that top
management understand the seriousness and scope of violations and allocate
resources to prevent their recurrence.
22
Therefore, FDA recently implemented a new policy instituting a fifteen-day
deadline for company responses. 23 The agency will not ordinarily delay issuance of
a warning letter in order to review a response to an FDA form 483 inspection report
that the agency receives more than fifteen business days after the 483 report was
issued.24 This program gives a company three weeks to review the report and
provide a response, which the agency believes is a reasonable time frame. FDA
plans to conduct a detailed review of timely responses before determining whether
to issue a warning letter.25 Further, FDA will address such responses in writing if it
subsequently issues a warning letter.26 FDA will evaluate this program after
eighteen months and decide if any changes are appropriate.27 In the meantime, the
agency makes clear that this policy is a guideline only, and it retains the discretion
to issue warning letters at any time.28
notice policy are based on the expectation that most individuals and firms will voluntarily comply with
the law.").
17. Id. at 4-1 to4-2.
18. Id. at 4-4.
19. Review of Post-Inspection Responses, 74 Fed. Reg. 40,211, 40,212 (Aug. 11, 2009); see also
Margaret Hamburg, Comm'r of Food & Drugs, U.S. Food & Drug Admin., Remarks at the Food &
Drug Law Institute: Effective Enforcement and Benefits to Public Health (Aug. 6, 2009), available at
http://www.fda.gov/NewsEvents/Speeches/ucm175983.htm ("[M]any of the enforcement actions that
the FDA has undertaken have been hampered by unreasonable delays. In some cases, serious violations
have gone unaddressed for far too long.").
20. Review of Post-inspection Responses, 74 Fed. Reg. at 40,212.
21. Id.
22. Id.
23. Id.; Hamburg, supra note 19.
24. Review of Post-Inspection Responses, 74 Fed. Reg. at 40,212.
25. Id.
26. Id.
27. Id.
28. Id.
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As another part of this initiative, OCC will no longer review every warning
letter before issuance.29 In 2001, the HHS Deputy Secretary had required OCC to
review every FDA warning letter to "further consistency and accountability. '30 The
number of warning letters the agency issued dropped after this policy began. 31 FDA
now believes this change will benefit the public health by permitting letters to
move forward through a more streamlined process.32 OCC will continue to review
certain categories of letters involving controversial or sensitive issues. This change
in policy will also be evaluated in the future to see if modifications are appropriate.
A third important change in this area is FDA's creation of a formal warning
letter "close-out" process.33 Following the issuance of a warning letter, FDA will
seek to determine whether a company has fully corrected the violations raised in
the letter.34 This will usually involve a re-inspection. If the company meets the
appropriate standards, FDA will provide a "close-out" letter, indicating that they
have successfully addressed the issues in the warning letter.35 To keep the public
informed, FDA will indicate on its website when a firm has received a "close-out"
letter.
36
III. PROMOTION USING THE INTERNET AND SOCIAL MEDIA
Another priority area for FDA is the regulation of product promotion
involving the Internet and social media tools. More and more companies are using
the Internet to disseminate information about their products.37 Social media-
websites whose content is primarily created by site-users rather than site-owners-
are playing an increasing role as well.38 Many FDA laws and regulations were
29. See Hamburg, supra note 19 (stating that the FDA will limit warning letter review only to the
critical legal issues).
30. Memorandum from Claude Allen, Deputy Secretary, U.S. Dep't of Health & Human Servs., to
Bernard Schwetz, Acting Comm'r of Food & Drugs, U.S. Food & Drug Admin. (Nov. 29,2001).
31. Mike Mitka, Report Criticizes Lack of FDA Oversight, 296 JAMA 920, 920 (2006) ("[T]he
number of warning letters issued ... decreased from 1154 in 2000 to 535 in 2005 and represented a 15-
year low."); see also U.S. Food & Drug Admin., Inspections, Compliance, Enforcement, and Criminal
Investigations: Warning Letters, http://www.fda.gov/ICECl/EnforcementActions/WamingLetters/
default.htm (documenting the warning letters issued since 1996) (last visited May 31, 2010).
32. Hamburg, supra note 19.
33. See id. (explaining the formal warning letter "close-out" process as an official determination
that a business has successfully complied with all the necessary corrective measures raised in the FDA
correspondence).
34. Id.
35. Id.
36. Id.
37. E.g., Promotion of FDA-Regulated Medical Products on the Internet; Notice of Public Meeting,
61 Fed. Reg. 48,707, 48,707 (Sept. 16, 1996) ("With the recent dramatic increases in the number of
users on the Internet ... companies, including manufacturers and distributors of products regulated by
FDA, are looking at the Internet as a medium for disseminating information about their products.").
38. Tony Blank, Vice Pres., Cardiovascular Reg. Affairs, Boston Scientific Corp., Presentation at
the FDA Public Hearing on Promotion of FDA-Regulated Medical Products Using the Internet and
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created before this technology was prevalent or even before it existed at all. The
agency is now evaluating how its statutes, regulations, and policies should be
applied (or changed) to meet these challenges.
Existing laws provide an initial framework for FDA's approach to these
issues. Under the Food, Drug, and Cosmetic Act,39 the agency has the responsibility
for regulating the labeling of prescription drugs and medical devices and the
advertising of prescription drugs and restricted medical devices. 40 The Act defines
labeling as "all labels and other written, printed, or graphic" materials "upon" or
"accompanying" an article. 4' The Supreme Court interpreted the term
"accompanying" broadly in the landmark case, Kordel v. United States.42
Following this broad interpretation, FDA's regulations state that labeling may
include brochures, mailing pieces, detailing pieces, calendars, price lists, letters,
motion picture films, and sound recordings. 43 Labeling must be truthful and non-
misleading.44 FDA also regulates the advertising for prescription drugs, biologics,
and restricted devices. 45 The Act does not define the word advertisement, but FDA
interprets the term to include information (other than labeling) that is intended to
promote a product, including "advertisements in published journals, magazines,
other periodicals, and newspapers, and advertisements broadcast through media
such as radio, television, and telephone communication systems.
' 46
A prescription drug is misbranded unless its advertising includes a "true
statement of . . . information in brief summary relating to side effects,
contraindications, and effectiveness" of the product.47 FDA's regulations require
that a "true statement" must not be false or misleading about side effects and it
must disclose relevant material facts.48  These regulations also require
Social Media Tools (Nov. 12, 2009), available at http://www.fda.gov/downloads/AboutFDA/
CentersOffices/CDER/UCM193462.pdf ("[S]ocial media ... is a growing space and a space of great
interest to the medical device industry ....").
39. 21 U.S.C. §§ 301-399a (2006 & West Supp. 2009).
40. See id. § 352 (describing the labeling requirements for drugs and devices); id. § 353b ("The
Secretary may require the submission of any television advertisement for a drug ... for review...
before dissemination .... ); id. § 360e(c)(1)(F) (requiring submission of "specimens of the labeling
proposed to be used" for a device subject to premarket approval).
41. Id. § 321(m).
42. 335 U.S. 345, 349 (1948) ("[T]he phrase 'accompanying such article' is not restricted to labels
that are on or in the article or package that is transported.").
43. 21 C.F.R. § 202.1(l)(2) (2009).
44. 21 U.S.C. § 352(a).
45. 21 C.F.R. § 202; see also Promotion of FDA-Regulated Medical Products on the Internet;
Notice of Public Meeting, 61 Fed. Reg. 48,707, 48,708 (Sept. 16, 1996) ("The Federal Food, Drug, and
Cosmetic Act... and its implementing regulations define the conditions under which human and animal
drugs, biologics, and medical devices shall be advertised and otherwise promoted . .
46. 21 C.F.R. § 202.1(l)(1).
47. 21 U.S.C. § 352(n).
48. 21 C.F.R. § 202.1(e)(5)(i), (iii).
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advertisements "to present a fair balance between information relating to side
effects and contraindications and information relating to effectiveness of the drug
.... A9 Fair balance means that the information provided in each of these
categories must be "comparable in depth and detail. The Act similarly
regulates advertising for restricted devices."
How to apply these principles to Internet promotion is not always obvious. No
existing FDA statutes or regulations specifically address Internet promotion. While
some Intemet promotional efforts are substantially similar in presentation and
content to promotional materials in traditional media, others are not. The Internet's
unique technological features include presentation and content options that may
have important implications in this area.
Since the agency first examined these issues at a public meeting in 1996,52
new Internet tools and technologies have multiplied.53 Internet platforms now
include blogs (diary or journal-type entries), microblogs (short blogs, such as
Twitter), podcasts (audio/video files), social networks (Facebook, Linkedln, etc.),
video sharing (hosting services such as YouTube), widgets (on-screen live content
such as weather reports and news updates), chatrooms (forums for multiple users to
ask questions and post comments), and wikis (web content that users can edit).54
FDA has called for public comment into regulatory issues surrounding these
matters. 55 The agency requests input on a number of specific questions. For what
communications should companies be held accountable? As a general matter, FDA
holds manufacturers, packers, and distributors responsible for any communications
they create, or that anyone acting on their behalf influences or controls, in whole or
in part (this covers, for example, statements made by advertising agencies). 6 How
should these principles apply to an Internet chatroom a company creates for
members of the public to post comments on their products? Should it matter
whether a company reviews and edits the comments or simply posts them
automatically? Should it matter whether a company affirmatively reaches out to
specific people to request comments or merely provides an open public forum for
anyone to comment?
Another significant question involves how companies can meet their
regulatory obligations given the real-time nature and space limitations of certain
49. Id. § 202.1(e)(5)(ii).
50. Id.
51. 21 U.S.C. § 352(q).
52. Promotion of FDA-Regulated Medical Products on the Internet; Notice of Public Meeting, 61
Fed. Reg. 48,707 (Sept. 16, 1996).
53. Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet
and Social Media Tools; Notice of Public Hearing, 74 Fed. Reg. 48,083, 48,085 (Sept. 21, 2009).
54. Id.
55. Id.
56. Id. at 48,086.
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Internet communication tools. FDA regulations require that promotional
communications must provide a "fair balance" between risk and benefit
information (unless the communication is a "reminder" advertisement that
mentions the name of the product without making any claims about it).57 Further,
each part of a communication must contain risk information necessary to qualify
any representations made about the drug in that part.
58
What are the implications of these provisions to Internet tools that have
limited space? Twitter, for example, requires its messages to be 140 characters or
less, and Google limits "sponsored links" (short advertisements on search results
pages with links to company web pages) to twenty-five characters for the title and
seventy characters for the ad text. On this issue, FDA issued fourteen letters on
April 2, 2009, to companies that advertised products by way of "sponsored links."59
The letters said these links misbranded the products by making representations
about efficacy without communicating associated risk information.
60
The agency would also like comment on the situation where misinformation
about a company's products (including discussion of unapproved uses) exists on a
website outside its control, such as a blog, social networking site, or wiki.6' Some
companies have attempted to correct such misinformation, but others have
expressed concern that doing so could make them responsible for all other
information on the website.62 A related issue involves the use of links. 63 Does the
law permit a company to sponsor a website that links to websites owned by other
organizations (such as support groups) that contain information about unapproved
uses of the company's products?
Finally, there are important questions about adverse event reporting involving
the Internet. 64 The law requires companies to provide information about adverse
events involving their products to FDA.65 In March 2001, FDA issued a draft
guidance for industry entitled Postmarketing Safety Reporting for Human Drug and
57. 21 C.F.R. § 202.1(e)(5)(ii) (2009).
58. Id. § 202.1(e)(3)(i).
59. See U.S. Food & Drug Admin., U.S. Dep't of Health & Human Servs., Drugs: Warning Letters
2009, http://www.fda.gov/Drugs/GuidanceComplianceRegulatorylnformation/EnforcementActivitiesby
FDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompaniesUCM055773 (last visited
May 31, 2010) (showing specific companies that received warning letters).
60. E.g., Letter from Shefali Doshi, Regulatory Review Officer, U.S. Food & Drug Admin., to
Amit Patel, Associate Dir., Regulatory Advertising & Promotion, Johnson & Johnson Pharmaceutical
Services, L.L.C. (Apr. 2, 2009), available at http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatorylnformation/EnforcementActivitiesbyFDA/WamingLettersandNoticeof
ViolationLetterstoPharmaceuticalCompaniesfUCM143484.pdf.
61. Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet
and Social Media Tools; Notice of Public Hearing, 74 Fed. Reg. at 48,086.
62. Id.at 48,087.
63. See id. (discussing the appropriate use of links to product information).
64. Id.
65. 21 C.F.R. §§ 310.305,314.80, 314.98, 514.80, 600.80, 803.1-58 (2009).
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Biological Products Including Vaccines.66 This document stated that companies
with postmarketing reporting obligations must report to FDA any adverse events
that they learn about on Internet sites that they sponsor if they have knowledge of
four things: an identifiable reporter, an identifiable patient, a suspect drug, and an
adverse experience suspected to be due to the drug.67 Companies are not
responsible for reviewing Internet sites they do not sponsor, but if they become
aware of an adverse event on such a site, they should review it to determine if they
should report it to FDA.68 The agency is interested in learning about companies'
experiences in this regard, what their practices have been, what challenges they
face, and what uncertainties remain.
IV. TOBACCO REGULATION
One of the most important recent developments at FDA is the enactment of
the Family Smoking Prevention and Tobacco Control Act.69 Tobacco use is the
leading preventable cause of death and disease in the United States.7 ° Smoking and
exposure to second-hand smoke cause approximately 443,000 deaths every year.71
Smokers die thirteen to fourteen years earlier than nonsmokers.72 Seventy percent
of smokers want to quit.73 Tobacco causes $193 billion in lost productivity and
medical costs each year.74 More deaths are caused each year by tobacco use than by
66. CTR. FOR DRUG EVALUATION & RESEARCH & CTR. FOR BIOLOGICS EVALUATION &
RESEARCH, U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: POSTMARKETING SAFETY
REPORTING FOR HUMAN DRUG AND BIOLOGICAL PRODUCTS INCLUDING VACCINES (2001), available at
http://www.fda.gov/downloads/BiologicsBloodVaceines/GuidanceComplianceRegulatorylnformation/G
uidances/Vaccines/ucm092257.pdf.
67. Id. at 8.
68. Id. at 21.
69. Pub. L. No. 111-31, 123 Stat. 1776 (2009).
70. E.g., Ctrs. for Disease Control & Prevention, U.S. Dep't of Health & Human Servs., High
School Students Who Tried to Quit Smoking Cigarettes-United States, 2007, 58 MORBIDITY &
MORTALITY WKLY. REP. 428, 428 (2009), available at http://www.cdc.gov/mmwr/pdf/wk/mm5816.pdf.
See also NAT'L CTR. FOR HEALTH STATISTICS, CTRS. FOR DISEASE CONTROL & PREVENTION, PUB. NO.
2009-1232, HEALTH, UNITED STATES, 2008, at 84-85 (2009), available at
http://www.cdc.gov/nchs/data/hus/hus08.pdf (discussing tobacco use in the United States).
71. Ctrs. for Disease Control & Prevention, U.S. Dep't of Health & Human Servs.,
Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States,
2000-2004, 57 MORBIDITY & MORTALITY WKLY. REP. 1226, 1226 (2008), available at
http://www.cdc.gov/mmwr/PDF/wk/mm5745.pdf.
72. Ctrs. for Disease Control & Prevention, U.S. Dep't of Health & Human Servs., Annual
Smoking-Attributable Mortality, Years of Potential Life Lost, and Economic Costs-United States, 1995-
1999, 51 MORBIDITY & MORTALITY WKLY. REP. 300, 301 (2002), available at
http://www.cdc.gov/mmwr/PDF/wk/mm5114.pdf.
73. Ctrs. for Disease Control & Prevention, U.S. Dep't of Health & Human Servs., Cigarette
Smoking Among Adults-United States, 2000, 51 MORBIDITY & MORTALITY WKLY. REP. 642, 642
(2002), available at http://www.cdc.gov/mmwr/PDF/wk/mm5129.pdf.
74. Ctrs. for Disease Control & Prevention, supra note 71, at 1228.
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all deaths from human immunodeficiency virus (HIV), illegal drug use, alcohol
use, motor vehicle injuries, suicides, and murders combined.75
Cigarette smoking rates have been declining, but the decline may be reaching
a plateau. In 1955, 54% of men and 24% of women smoked; by 2007, these rates
had dropped to 22% of men and 17% of women.76 For youth, however, recent
smoking rates have fluctuated. In 1991, 28% of high school students smoked; in
1997, this figure rose to 36%; in 2007, it was 20%.77 The number of youth who
smoke is crucial, as nearly 90% of smokers start by the age of eighteen.78
FDA's goals in regulating tobacco are to reduce youth tobacco use, promote
public understanding of contents and consequences of tobacco use, develop a base
of scientific knowledge, and begin meaningful product regulation to reduce the toll
of tobacco-related disease, disability, and death.79 The Act provides the agency
with important tools to accomplish this mission: the authority to establish tobacco
product standards, 80 the requirement that manufacturers receive pre-market
approval for certain products, 81 a requirement that manufacturers report ingredient
and constituent data for their products,82 the authority to promulgate advertising
standards and require warning labels,83 and the power to enforce violations of the
law.
84
75. Ali H. Mokdad, Actual Causes of Death in the United States, 2000, 291 JAMA 1238, 1240 tbl.2
(2004).
76. JOHN R. PLEIS & JACQUELINE W. LUCAS, CTRS. FOR DISEASE CONTROL & PREVENTION, PUB.
NO. 2009-1568, SUMMARY HEALTH STATISTICS FOR U.S. ADULTS: NATIONAL HEALTH INTERVIEW
SURVEY, 2007, at 71 tbl.25 (2009), available at http://www.cdc.gov/nchs/data/series/srlO/
sr10_240.pdf, Ctrs. for Disease Control & Prevention, U.S. Dep't of Health & Human Servs.,
Surveillance for Selected Tobacco-Use Behaviors-United States, 1900-1994, 43 MORBIDITY &
MORTALITY WKLY. REP. (SURVEILLANCE SUMMARIES) 35 (1994), available at
http://www.cdc.gov/mmwr/PDF/ss/ss4303.pdf; see also GARY A. GIOV1NO ET AL., ROBERT WOOD
JOHNSON FOUND., CIGARETrE SMOKING PREVALENCE AND POLICIES IN THE 50 STATES: AN ERA OF
CHANGE 11 fig.3 (2009), available at http://www.impacteen.org/generalareaPDFs/
chartbook_finalO71009.pdf (showing the reduction in cigarette smoking from 1955 to 2007).
77. Danice K. Eaton et al., Ctrs. for Disease Control & Prevention, Youth Risk Behavior
Surveillance-United States, 2007, 57 MORBIDITY & MORTALITY WKLY. REP. (SURVEILLANCE
SUMMARIES) 32 (2008), available at http://www.cdc.gov/mmwr/pdf/ss/ss5704.pdf.
78. Donald W. Garner & Richard J. Whitney, Protecting Children from Joe Camel and His
Friends: A New First Amendment and Federal Preemption Analysis of Tobacco Billboard Regulation,
46 EMORY L.J. 479, 533 (1997); Nancy A. Rigotti et al., The Effect of Enforcing Tobacco-Sales Laws on
Adolescents'Access to Tobacco and Smoking Behavior, 337 NEW ENG. J. MED. 1044, 1044 (1997).
79. Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, sec. 3, 123 Stat.
1776, 1781 (2009).
80. Id. sec. 101, § 907, 123 Stat. at 1799 (to be codified at 21 U.S.C. § 387g).
81. Id. sec. 101, § 903(b), 123 Stat. at 1788 (to be codified at 21 U.S.C. § 387c).
82. Id. sec. 101, § 904(a)(3), 123 Stat. at 1781 (to be codified at 21 U.S.C. § 387d).
83. Id. sees. 201-202, 123 Stat. at 1842-46 (to be codified at 15 U.S.C. §§ 1333-1334).
84. Id. sec. 105(a), 123 Stat. at 1841 (to be codified at 21 U.S.C. § 387f-1).
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FDA's tobacco program will be funded entirely by user fees paid by
industry.8 5 Companies will pay based upon their share of the United States
market.8 6 The Act sets the FY2010 budget at $235 million and provides for annual
5.8% raises until 2019, when the budget will be set at $712 million.
87
FDA has been very active since the law's passage. Agency representatives
have met with State and local officials, tobacco industry representatives, and public
health advocates to learn more about the field.88 The agency is well on its way to
staffing a new Center for Tobacco Products, with a Center Director and dedicated
office facilities.
8 9
Interagency cooperation will be crucial. In particular, FDA will be working
closely with the Centers for Disease Control on public health issues, including their
Office on Smoking and Health and National Center for Environmental Health. The
National Institutes of Health will be an important partner in tobacco research. The
Substance Abuse and Mental Health Services Administration will be invaluable in
outreach and surveillance issues. FDA plans to work with state and local agency
partners to create a unified approach to tobacco control.
In the legal arena, on September 22, 2009, the statutory ban on cigarettes
containing certain characterizing flavors went into effect.90 The ban on candy and
fruit-flavored cigarettes recognizes the importance of reducing the number of youth
who smoke and then become addicted.9' On September 30, 2009 FDA issued a
draft guidance document covering the prohibition against marketing a tobacco
product in combination with another FDA-regulated product. 92 In October, the
agency issued two draft guidance documents to assist industry, one on statutory
registration and product listing requirements, and the other on requirements for
ingredient listing.
93
85. id. sec. 101, § 919(a), 123 Stat. at 1826 (to be codified at 21 U.S.C. § 387s).
86. Id. sec. 101, § 919(b)(2)(B)(ii), 123 Stat. at 1827.
87. Id. sec. 101, § 919(b), 123 Stat. at 1826-27.
88. See U.S. Food & Drug Admin., Tobacco Products: Center for Tobacco Products Update,
http://www.fda.govfTobaccoProducts/NewsEvents/ucm I89487.htm (last visited May 31, 2010).
89. See Press Release, U.S. Food & Drug Admin., FDA Launches New Center for Tobacco
Products (Aug. 19, 2009), bttp://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm179410.htm (introducing the newly implemented program, including the new director position and
facility location).
90. U.S. Food & Drug Admin., supra note 88.
91. Press Release, U.S. Food & Drug Admin., Candy and Fruit Flavored Cigarettes Now Illegal in
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http://www.fda.govlNewsEvents/NewsroomlPressAnnouncements/2009/ucml 83211 .htm.
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CONCLUSION
FDA's mission takes on new meaning as regulatory issues emerge.
Developing technologies, a changing legislative landscape, and evolving public
needs require the agency to adapt to serve its purpose. Working with the public, the
courts, the Congress, and other government agencies, FDA seeks to maximize its
effectiveness in protecting and promoting the public health.
PRODUCT ESTABLISHMENTS (2009), available at http://www.fda.gov/downloads/robaccoProducts/
GuidanceComplianceRegulatorylnformation/UCM186955.pdf; CTR. FOR TOBACCO PRODUCTS, U.S.
FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: LISTING OF INGREDIENTS IN TOBACCO
PRODUCTS (2009), available at http://www.fda.gov/downloads/TobaccoProducts/
GuidanceComplianceRegulatorylnformation/UCM I 88496.pdf.
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